

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Tafluprost Formulation

Version 4.1	Revision Date: 14.04.2025	SDS Number: 564740-00021	Date of last issue: 03.12.2024 Date of first issue: 15.03.2016
----------------	------------------------------	-----------------------------	---

## SECTION 1: Identification of the substance/mixture and of the company/undertaking

### 1.1 Product identifier

Trade name : Tafluprost Formulation

### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
Kilsheelan  
Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

### 1.4 Emergency telephone number

+1-908-423-6000

---

## SECTION 2: Hazards identification

### 2.1 Classification of the substance or mixture

#### Classification (REGULATION (EC) No 1272/2008)

Not a hazardous substance or mixture.

### 2.2 Label elements

#### Labelling (REGULATION (EC) No 1272/2008)

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Tafluprost Formulation

Version  
4.1

Revision Date:  
14.04.2025

SDS Number:  
564740-00021

Date of last issue: 03.12.2024  
Date of first issue: 15.03.2016

**Ecological information:** The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

**Toxicological information:** The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

---

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Tafluprost	209860-87-7	Acute Tox. 4; H302 Eye Irrit. 2; H319 Repr. 1B; H360D STOT SE 1; H370 (Lungs, Cardio- vascular system) STOT RE 1; H372 (Lungs, Cardio- vascular system) Aquatic Chronic 4; H413	>= 0,0002 - < 0,0025

For explanation of abbreviations see section 16.

---

## SECTION 4: First aid measures

### 4.1 Description of first aid measures

Protection of first-aiders : No special precautions are necessary for first aid responders.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.  
Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Tafluprost Formulation

Version 4.1	Revision Date: 14.04.2025	SDS Number: 564740-00021	Date of last issue: 03.12.2024 Date of first issue: 15.03.2016
----------------	------------------------------	-----------------------------	---

### 4.2 Most important symptoms and effects, both acute and delayed

None known.

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

---

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

### 5.3 Advice for firefighters

Special protective equipment for firefighters : Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Tafluprost Formulation

Version  
4.1

Revision Date:  
14.04.2025

SDS Number:  
564740-00021

Date of last issue: 03.12.2024  
Date of first issue: 15.03.2016

cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up

- : Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

Technical measures

- : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation

- : Use only with adequate ventilation.

Advice on safe handling

- : Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment

Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures

- : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

- : Keep in properly labelled containers. Store in accordance with the particular national regulations.

Advice on common storage

- : Do not store with the following product types:  
Strong oxidizing agents  
Gases

### 7.3 Specific end use(s)

Specific use(s)

- : No data available

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Tafluprost Formulation

Version  
4.1

Revision Date:  
14.04.2025

SDS Number:  
564740-00021

Date of last issue: 03.12.2024  
Date of first issue: 15.03.2016

### SECTION 8: Exposure controls/personal protection

#### 8.1 Control parameters

##### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Tafluprost	209860-87-7	TWA	0.002 µg/m <sup>3</sup> (OEB 5)	Internal
	Further information: Skin, Eye			
		Wipe limit	0.02 µg/100 cm <sup>2</sup>	Internal

##### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
Glycerine	Workers	Inhalation	Long-term local effects	56 mg/m <sup>3</sup>
	Consumers	Ingestion	Long-term systemic effects	229 mg/kg bw/day
	Consumers	Inhalation	Long-term local effects	33 mg/m <sup>3</sup>

##### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Glycerine	Fresh water	0,885 mg/l
	Marine water	0,0885 mg/l
	Intermittent use/release	8,85 mg/l
	Sewage treatment plant	1000 mg/l
	Fresh water sediment	3,3 mg/kg dry weight (d.w.)
	Marine sediment	0,33 mg/kg dry weight (d.w.)
	Soil	0,141 mg/kg dry weight (d.w.)

#### 8.2 Exposure controls

##### Engineering measures

The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Tafluprost Formulation

Version  
4.1

Revision Date:  
14.04.2025

SDS Number:  
564740-00021

Date of last issue: 03.12.2024  
Date of first issue: 15.03.2016

---

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

### Personal protective equipment

Eye/face protection	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection	
Material	: Chemical-resistant gloves
Remarks	: Consider double gloving.
Skin and body protection	: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Filter should conform to NS EN 14387
Filter type	: Organic vapour type (A)

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

Physical state	: Aqueous solution
Colour	: clear
Odour	: No data available
Odour Threshold	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Tafluprost Formulation

Version 4.1	Revision Date: 14.04.2025	SDS Number: 564740-00021	Date of last issue: 03.12.2024 Date of first issue: 15.03.2016
----------------	------------------------------	-----------------------------	---

---

Lower explosion limit / Lower flammability limit : No data available

Flash point : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity  
Viscosity, kinematic : No data available

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Vapour pressure : No data available

Relative density : No data available

Density : No data available

Relative vapour density : No data available

Particle characteristics  
Particle size : No data available

### 9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Tafluprost Formulation

---

Version 4.1	Revision Date: 14.04.2025	SDS Number: 564740-00021	Date of last issue: 03.12.2024
			Date of first issue: 15.03.2016

---

### 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

### 10.4 Conditions to avoid

Conditions to avoid : None known.

### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

## SECTION 11: Toxicological information

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

##### Tafluprost:

Acute oral toxicity : LD50 (Rat): 665 mg/kg  
LD50 (Rat): > 100 mg/kg  
Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration) : (Dog): 3 mg/kg  
Application Route: Intravenous  
Target Organs: Cardio-vascular system

#### Skin corrosion/irritation

Not classified based on available information.

#### Serious eye damage/eye irritation

Not classified based on available information.

#### Components:

##### Tafluprost:

Species : Monkey  
Result : No eye irritation

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Tafluprost Formulation

Version  
4.1

Revision Date:  
14.04.2025

SDS Number:  
564740-00021

Date of last issue: 03.12.2024  
Date of first issue: 15.03.2016

### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

#### Components:

##### Tafluprost:

Test Type : Maximisation Test  
Exposure routes : Dermal  
Species : Guinea pig  
Result : Not a skin sensitizer.

### Germ cell mutagenicity

Not classified based on available information.

#### Components:

##### Tafluprost:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: negative

### Carcinogenicity

Not classified based on available information.

#### Components:

##### Tafluprost:

Species : Rat  
Application Route : Subcutaneous  
Exposure time : 24 Months  
Result : negative

Species : Mouse  
Application Route : Subcutaneous  
Exposure time : 18 Months  
Result : negative

### Reproductive toxicity

Not classified based on available information.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Tafluprost Formulation

Version  
4.1

Revision Date:  
14.04.2025

SDS Number:  
564740-00021

Date of last issue: 03.12.2024  
Date of first issue: 15.03.2016

### Components:

#### **Tafluprost:**

Effects on fertility

: Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Intravenous injection  
Fertility: NOAEL: 100 µg/kg  
Result: No effects on fertility

Effects on foetal development

: Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intravenous injection  
Developmental Toxicity: LOAEL: 10 µg/kg  
Result: Malformations were observed., Reduced foetal weight

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intravenous injection  
Developmental Toxicity: NOAEL: 3 µg/kg

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Intravenous injection  
Developmental Toxicity: LOAEL: 0,03 µg/kg  
Result: Malformations were observed.

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Intravenous injection  
Developmental Toxicity: NOAEL: 0,01 µg/kg

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intravenous injection  
Developmental Toxicity: LOAEL: 1 µg/kg

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intravenous injection  
Developmental Toxicity: NOAEL: 0,3 µg/kg

Reproductive toxicity - Assessment

: Clear evidence of adverse effects on development, based on animal experiments.

### **STOT - single exposure**

Not classified based on available information.

### Components:

#### **Tafluprost:**

Target Organs  
Assessment

: Lungs, Cardio-vascular system  
: Causes damage to organs.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Tafluprost Formulation

Version  
4.1

Revision Date:  
14.04.2025

SDS Number:  
564740-00021

Date of last issue: 03.12.2024  
Date of first issue: 15.03.2016

### STOT - repeated exposure

Not classified based on available information.

#### Components:

##### **Tafluprost:**

Target Organs : Lungs, Cardio-vascular system  
Assessment : Causes damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

#### Components:

##### **Tafluprost:**

Species	:	Rat
LOAEL	:	0,01 mg/kg
Application Route	:	Intravenous
Exposure time	:	6 Months
Target Organs	:	Cardio-vascular system, Blood, Bone marrow, Kidney, Liver, spleen
Species	:	Dog
NOAEL	:	0,0001 mg/kg
LOAEL	:	0,001 mg/kg
Application Route	:	Intravenous
Exposure time	:	39 Weeks
Target Organs	:	Cardio-vascular system, Eye
Symptoms	:	Dilatation of the pupil

### Aspiration toxicity

Not classified based on available information.

## 11.2 Information on other hazards

### Endocrine disrupting properties

Not classified based on available information.

#### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### Experience with human exposure

#### Components:

##### **Tafluprost:**

Eye contact : Symptoms: dryness of the eyes, Blurred vision

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Tafluprost Formulation

Version 4.1	Revision Date: 14.04.2025	SDS Number: 564740-00021	Date of last issue: 03.12.2024 Date of first issue: 15.03.2016
----------------	------------------------------	-----------------------------	---

---

### SECTION 12: Ecological information

#### 12.1 Toxicity

No data available

#### 12.2 Persistence and degradability

No data available

#### 12.3 Bioaccumulative potential

##### Components:

##### **Tafluprost:**

Partition coefficient: n-octanol/water : log Pow: 4,5

#### 12.4 Mobility in soil

No data available

#### 12.5 Results of PBT and vPvB assessment

##### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

#### 12.6 Endocrine disrupting properties

##### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

#### 12.7 Other adverse effects

No data available

---

### SECTION 13: Disposal considerations

#### 13.1 Waste treatment methods

Product	: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Tafluprost Formulation

Version 4.1	Revision Date: 14.04.2025	SDS Number: 564740-00021	Date of last issue: 03.12.2024 Date of first issue: 15.03.2016
----------------	------------------------------	-----------------------------	---

If not otherwise specified: Dispose of as unused product.

## SECTION 14: Transport information

### 14.1 UN number or ID number

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

### 14.2 UN proper shipping name

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

### 14.3 Transport hazard class(es)

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

### 14.4 Packing group

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA (Cargo)	:	Not regulated as a dangerous good
IATA (Passenger)	:	Not regulated as a dangerous good

### 14.5 Environmental hazards

Not regulated as a dangerous good

### 14.6 Special precautions for user

Not applicable

### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Tafluprost Formulation

Version  
4.1

Revision Date:  
14.04.2025

SDS Number:  
564740-00021

Date of last issue: 03.12.2024  
Date of first issue: 15.03.2016

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)

: Conditions of restriction for the following entries should be considered: Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

REACH - List of substances subject to authorisation (Annex XIV)

: Not applicable

Regulation (EU) No 2024/590 on substances that deplete the ozone layer

: Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast)

: Not applicable

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals

: Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

## SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Tafluprost Formulation

Version  
4.1

Revision Date:  
14.04.2025

SDS Number:  
564740-00021

Date of last issue: 03.12.2024  
Date of first issue: 15.03.2016

lines.

### Full text of H-Statements

H302	: Harmful if swallowed.
H319	: Causes serious eye irritation.
H360D	: May damage the unborn child.
H370	: Causes damage to organs if swallowed.
H372	: Causes damage to organs through prolonged or repeated exposure if swallowed.
H413	: May cause long lasting harmful effects to aquatic life.

### Full text of other abbreviations

Acute Tox.	: Acute toxicity
Aquatic Chronic	: Long-term (chronic) aquatic hazard
Eye Irrit.	: Eye irritation
Repr.	: Reproductive toxicity
STOT RE	: Specific target organ toxicity - repeated exposure
STOT SE	: Specific target organ toxicity - single exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECL - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Tafluprost Formulation

Version  
4.1

Revision Date:  
14.04.2025

SDS Number:  
564740-00021

Date of last issue: 03.12.2024  
Date of first issue: 15.03.2016

---

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN